Black Seed Oil Ingredient Shows Hair Density Gains in Clinical Study

TriNutra has published results from a dermatologically supervised evaluation of B'utyQuin, its standardized black seed oil ingredient, formulated into a 5% scalp lotion and tested in 22 adult men and women over 28 days.¹

The study, conducted by J.S. Hamilton Poland under Good Clinical Practice standards, measured hair density instrumentally and tracked hair loss through a standardized dry hair loss test, alongside dermatological tolerance assessments at baseline and study completion.

Participant-reported outcomes were strong: 82% said they noticed a visible reduction in hair loss, and the same share reported visible stimulation of new growth. Roughly three-quarters, 77%, described their hair as stronger and more voluminous, while 95% found the formula gentle and well-suited to the scalp.

"B'utyQuin is a potent active ingredient that helps support a healthy scalp environment and hair follicle vitality," said Liki von Oppen-Bezalel, PhD, business development director at TriNutra, in the company's announcement.² "These results demonstrate how B'utyQuin can deliver noticeable hair and scalp health benefits in a relatively short period of time."

For formulators evaluating scalp-health actives, the data adds an instrumentally measured dataset to a category where many ingredient claims rely on self-reported outcomes alone.

What Did the Study Measure, and How Was It Designed?

The evaluation combined instrumental hair density measurements with a standardized dry hair loss test and dermatologist-supervised tolerance checks, comparing baseline results to those recorded after 28 days of daily lotion use.

That design allows for objective, device-measured outcomes rather than relying solely on participant perception, though the study did not include a placebo or vehicle-only control group, so the extent to which the observed changes are attributable specifically to B'utyQuin, rather than to consistent scalp massage, moisturization, or natural fluctuation in hair density over 4 weeks, cannot be isolated from the published summary alone.

How Does This Fit Into the Broader Hair Loss Treatment Landscape?

Hair thinning and androgenetic alopecia remain common concerns with a treatment landscape still centered on topical and oral minoxidil, which has decades of randomized, placebo-controlled trial data behind it and remains the most studied nonprescription option for hair density.³

Cosmetic ingredients like B'utyQuin are generally positioned as scalp-health or hair-appearance support rather than as treatments for diagnosed alopecia, a distinction that matters for how manufacturers can lawfully frame finished-product claims.

TriNutra's CEO, Morris Zelkha, described additional proposed mechanisms in the announcement, stating that research shows B'utyQuin "boosts mitochondrial function, ATP production, and provides antimicrobial benefits against pathogens and improved healthy microbiome diversity in a prebiotic-like effect."²

What Are the Limitations of This Study?

The trial's small sample size of 22 participants and absence of a control arm limit how confidently the reported effects can be generalized.

References

1. Kalinowska O, von Oppen-Bezalel L. The effect of black seed oil scalp lotion on hair density and hair loss reduction: a controlled instrumental assessment. SOFW Journal. 2026;152(1-2):26-30.

2. New clinical study demonstrates B'utyQuin significantly improves hair density. TriNutra. September 2, 2026. Accessed September 3, 2026. Press release provided via email.

3. Gupta AK, Talukder M, Shemar A, Piraccini BM, Tosti A. Low-dose oral minoxidil for alopecia: a comprehensive review. Skin Appendage Disord. 2023;9(6):423-437. doi:10.1159/000531890